Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

Aim: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population. Materials and methods: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medical economics 2017-06, Vol.20 (6), p.555-564
Hauptverfasser:	Toth, Peter P., Danese, Mark, Villa, Guillermo, Qian, Yi, Beaubrun, Anne, Lira, Armando, Jansen, Jeroen P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Coronary Syndrome - economics Acute Coronary Syndrome - prevention & control Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - economics Anticholesteremic Agents - administration & dosage Anticholesteremic Agents - economics Atherosclerosis - economics Atherosclerosis - prevention & control burden of disease cardiovascular disease (CVD) Cardiovascular Diseases - economics Cardiovascular Diseases - prevention & control Cholesterol, LDL - drug effects Comorbidity Cost-Benefit Analysis cost-effectiveness Evolocumab Female Heart Failure - economics Heart Failure - prevention & control Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics low-density lipoprotein cholesterol (LDL-C) Male Models, Econometric PCSK9 inhibition Quality-Adjusted Life Years Risk Factors Secondary Prevention - economics Stroke - economics Stroke - prevention & control United States value-based pricing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!